National Cannabis Roundtable Applauds DEA’s Move: December Hearing On Rescheduling Set
The U.S. Drug Enforcement Administration (DEA) has scheduled a hearing on Dec. 2, 2024, to discuss the proposed reclassification of cannabis as a Schedule III substance under the Controlled Substances Act. This marks a crucial step in the ongoing process of cannabis rescheduling, drawing attention from industry leaders and stakeholders.
Saphira Galoob, executive director of the National Cannabis Roundtable (NCR) and upcoming speaker at the Benzinga Cannabis Capital Conference, issued a press release expressing her support for the hearing. Galoob also emphasizes the importance of utilizing every aspect of the administrative process.
“For significant decisions, it is only logical that all pieces of the administrative process are utilized, and a hearing reflects the gravity of …